GIGABYTE
21.5.2024 03:01:30 CEST | Business Wire | Press release
GIGABYTE Technology, a leading IT innovator, is at the forefront of advancing global industries through cloud and AI computing systems, enhancing user experiences through hardware innovation. At COMPUTEX 2024, GIGABYTE unveils groundbreaking products poised to define the AI era.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240517872510/en/
GIGABYTE Showcases a Whole Lot of Computing Power at COMPUTEX, Taking the AI-driven New Evolution Head-On (Graphic: Business Wire)
Building on last year’s success, GIGABYTE looks to solidify its AI leadership with the theme “ACCEVOLUTION,” reflecting the increasing demand for computing and GIGABYTE’s ability to “accelerate the next evolution.” With its largest-ever presence at COMPUTEX, GIGABYTE’s booth stands as the largest single-brand exhibit. Showcasing a wide range of products, solutions, and applications aligned with the AI trend, GIGABYTE covers key tech trends including AI computing, advanced connectivity, future mobility, immersive reality, sustainability, and innovation.
GIGABYTE’s remarkable advancements in AI server development in recent years have garnered widespread attention, as GIGABYTE introduced the G593-SD0, the world’s first and only NVIDIA-certified 5U AI server to efficiently support the HGX™ H100 8 x SXM5. GIGABYTE further expands its super AI server lineup with ARM-based AI servers featuring the next-generation Grace Hopper™ superchip, and AI servers supporting AMD’s next-gen superchips MI300X GPU and MI300A APU. This year, on top of the upgraded H200 GPU, with NVIDIA unveiling the Blackwell architecture, GIGABYTE will showcase ahead of schedule at its booth the latest high-density servers compatible with GPUs such as B100 and B200. The highly-anticipated GB200 will also be demonstrated in a liquid-cooled cabinet as GB200 NVL72, acting as one massive GPU that can achieve 30 times the inference performance of the same amount of H100 GPUs. This allows visitors not only to witness these innovations firsthand but also to engage in discussions with professionals about the future of AI development and computing deployment.
As AI becomes ubiquitous, computing demand rises sharply in large data centers and AI startups. At this year’s COMPUTEX, GIGABYTE presents GIGA POD, a scalable rack integration solution, designed to meet data center-level deployments. Beyond showing GIGA POD’s comprehensive hardware and software integration and AI training optimization environments, on-site demonstrations will highlight its performance leadership and deployment flexibility.
GIGABYTE’s AI development encompasses GPU parallel computing, data storage, and network transmission in data centers. GIGABYTE’s R&D prowess is evident in industry-leading thermal and mechanical design, while modular design enables product diversity, speeding up time-to-market. At the booth, find servers for cloud to edge computing, high-performance to high-density storage, and computing options for SMBs and micro-enterprises, including DIY server motherboards tailored to AI development at various scales.
GIGABYTE’s green computing complements AI advancements perfectly. Innovations like Direct Liquid Cooling and Immersion Cooling redefine performance and efficiency, offering comprehensive setups for servers and cabinets. This enables servers with the latest chips from AMD, Intel, and NVIDIA to surpass traditional cooling limits, enhancing heat dissipation and computational density while ensuring stability. GIGABYTE’s sustainability commitment is evident in immersion cooling solutions, supporting technological advancements with optimal power usage.
GIGABYTE presents both robust AI model training capabilities and practical AI applications through industrial-grade embedded computers. Demonstrations span smart factories with AI-enabled machine vision and high-stability embedded computers for remote control, as well as retail bars utilizing panel PCs combined with AI recognition and big data analysis. Advancements in AI and next-generation CPU/GPU also bolster smart automotive applications, enhancing ADAS and in-vehicle Telematics devices.
In the consumer PC market, GIGABYTE leads with AI-enhanced products like motherboards, graphics cards, and AI gaming laptops. These feature stable AI computing power and innovative capabilities such as the AI Nexus in the AORUS 16X gaming laptop, offering applications like AI Power Gear and AI Boost. At our booth’s AI experience area, visitors can explore the latest AI applications and real-time interactions, including NVIDIA ACE and ChatRTX, delving immersively into cutting-edge AI technologies.
GIGABYTE is bringing an impressive products portfolio to COMPUTEX, demonstrating its capacity to accelerate the next evolution of technology in this changing AI landscape, and its abundance of computing solutions driven by the connectivity and velocity of data and AI can elevate businesses and empower individuals to thrive in the extra-fast growing and development time.
Visit GIGABYTE’s COMPUTEX event page.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240517872510/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom